Connect Biopharma Holdings Ltd - ADR Stock

$1.83

5.78%

Nasdaq, Aug 22, 10:00 pm CET

ISIN

US2075231017

Symbol

CNTB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Connect Biopharma Holdings Ltd - ADR Stock price

$1.83

-15.17 89.24% 5Y

Nasdaq, Closing price Fri, Aug 22 2025

+0.10 5.78%

ISIN

US2075231017

Symbol

CNTB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$96.2m

Enterprise Value

Net debt

Cash

Shares outstanding

Valuation (TTM | estimate)

P/E

negative | negative

P/S

3.7 | -

EV/Sales

- | -

EV/FCF

P/B

Financial Health

Equity Ratio

Return on Equity

ROCE

ROIC

Debt/Equity

Financials (TTM | estimate)

Revenue

$26.1m | $0.0

EBITDA

$-35.3m | -

EBIT

$-35.9m | $-263.0m

Net Income

$-28.5m | -

Free Cash Flow

$-38.9m

EPS

$-0.5

FCF per Share

Short interest

0.1%

Employees

Rev per Employee

$420.0k

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Get Started for Free Today

Connect Biopharma Holdings Ltd - ADR Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Connect Biopharma Holdings Ltd - ADR forecast:

8x Buy

89%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Connect Biopharma Holdings Ltd - ADR forecast:

Buy

89%

Hold

11%

Analyst Estimates with Stock Price Targets

Financial data from Connect Biopharma Holdings Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	26 26	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	23 23	- 87%
- Research and Development Expense	37 37	- 143%
EBITDA	-35 -35	- -136%
- Depreciation and Amortization	0.53 0.53	- 2%
EBIT (Operating Income) EBIT	-36 -36	- -138%
Net Profit	-29 -29	- -109%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Connect Biopharma Holdings Ltd - ADR Stock News

Neutral

GlobeNewsWire

●

11 days ago

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide

Company and Former Cincinnati Bengals Running Back Known for the “Ickey Shuffle” Collaborate to Raise Awareness and Drive Asthma Education with Focus on Acute Attacks SAN DIEGO and CINCINNATI, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company) and the Jovante Woods Foundation (the Foundation) today kicked off a collab...

Neutral

GlobeNewsWire

●

12 days ago

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations – – Presented positive data at ATS 2025 and EAACI 2025 supporting the potential of rademikibart to deliver differentiated efficacy and safety in patients with eosinophilic-driven type 2 asthma and COPD – – New drug application for rademikibart for the treatment of A...

Neutral

GlobeNewsWire

●

about one month ago

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

– Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformation and growth – SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company...

More Connect Biopharma Holdings Ltd - ADR News

Company Profile

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.

Head office	Cayman Islands
CEO	Barry Quart
Employees	62
Founded	2015
Website	www.connectbiopharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now